drug
zeleciment rostudirsen
Phase 2updated 7mo agoby $DYN Dyne Therapeutics, Inc.
Phase 2community read0 votes
indications
indications
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
News(4)
- Sarepta’s new CEO confident in clinical execution as DMD competitors close inSarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.biospace · 14d ago
- On the move: 4 rare disease companies hiring nowBiotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.biospace · 1mo ago
- 4 potential biotech M&A targets, plus a pretty sure bet from J&JPharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.biospace · 3mo ago
- Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ reviewIf approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…biospace · 4mo ago
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that